Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 4 sales; 650 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
Q1 2026 vs. Q4 2025
How the institutions holding Royalty Pharma plc changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Of which not filed for Q1 2026 | Q1 2026 | Change |
|---|---|---|---|---|
| Holders | 542 | 8 | 594 | +60 |
| Shares | 357.9M | 15.1M | 354.9M | +12.1M (+3.5%) |
| Value | $13.8B | $581.6M | $17.0B | +$3.76B (+28.4%) |
8 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (117)
Institutions that held Royalty Pharma plc at the end of Q1 2026 but not at the end of Q4 2025.
Showing the largest 100 of 117 by value.
Sold out (57)
Institutions that held Royalty Pharma plc at the end of Q4 2025 and filed for Q1 2026 without it.
Not filed for Q1 2026 yet (8)
Institutions that held Royalty Pharma plc at the end of Q4 2025 and haven't filed a 13F for Q1 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| Vanguard Group Inc | 9,934,612 | $383.9M |
| Norges Bank | 3,414,165 | $131.9M |
| Brandywine Global Investment Management, LLC | 1,579,252 | $61.0M |
| Forsta Ap-Fonden | 71,400 | $2.76M |
| Elevated Private Wealth, LLC | 29,557 | $1.14M |
| CIBC World Markets Corp | 14,250 | $550.6K |
| Global Retirement Partners, LLC | 7,550 | $291.7K |
| CIBC Private Wealth Group, LLC | 1,118 | $43.2K |